Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...
BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...
Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...
PARSIPPANY, N.J., February 20, 2025--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences.
Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...
Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...